INDV — Indivior Pharmaceuticals Inc stock price, charts and financials

QT65Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc (NASDAQ: INDV) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
36.50
-0.87-2.33%
OverviewShort InterestFilings
INDVQT65Indivior Pharmaceuticals Inc·NASDAQ
36.50-2.33%
Filing
Down 2.3% — Filed an 8-K material-event report (2026-08-03) — details in the filing.
Medium confidence
TA
Loading chart...
Screen all →
OCTVV+2.29%$17.40AMRX-1.96%$18.48LNTH-0.08%$101.11RGC-1.31%$6.05SUPN-5.98%$43.25BHC-8.00%$6.44RDY+0.25%$12.10HCM+0.17%$11.57
Snapshot
Index-P/E18.87EPS (ttm)1.98Insider Own1.86%Shs Outstand124.77MPerf Week-6.65%
Market Cap4.66BForward P/E9.27EPS next Y4.03Insider Trans-3.10%Shs Float112.13MPerf Month-6.11%
Enterprise Value5.00BPEG3.31EPS next Q-Inst Own-Short Float10.06%Perf Quarter-0.77%
Income251.00MP/S3.61EPS this Y88.17%Inst Trans-Short Ratio5.75Perf Half Y5.62%
Sales1.29BP/B-EPS next Y8.17%ROA20.97%Short Interest11.28MPerf YTD4.15%
Book/sh-1.15P/C26.64EPS next 5Y5.70%ROE-142.01%52W High41.81 -12.71%Perf Year85.00%
Cash/sh1.40P/FCF-EPS past 3/5Y-ROIC85.68%52W Low19.29 89.22%Perf 3Y59.02%
Dividend Est.-EV/EBITDA14.20Sales past 3/5Y11.20% 13.88%Gross Margin83.11%Volatility5.05% 3.69%Perf 5Y264.59%
Dividend TTM-EV/Sales3.87EPS Y/Y TTM13100.00%Oper. Margin33.31%ATR (14)1.59Perf 10Y114.15%
Dividend Ex-DateJun 16, 2016Quick Ratio0.66Sales Y/Y TTM8.67%Profit Margin19.44%RSI (14)35.23Recom2.00
Dividend Gr. 3/5Y-Current Ratio0.86EPS Q/Q134.15%SMA20-7.25%Beta1.12Target Price49.50
Payout0.00%Debt/Eq5.27Sales Q/Q19.17%SMA50-4.45%Rel Volume3.42Prev Close37.37
Employees838LT Debt/Eq-3.18EarningsOct 29SMA2008.21%Avg Volume1.95MPrice36.50
IPO DateDec 29, 2014Option/ShortYes / YesEPS/Sales Surpr.45.45% 16.19%Net Debt/EBITDA0.95Volume6,679,635Change-2.33%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedCraig-HallumBuy$50 → $53
Jun-18-26InitiatedBarclaysOverweight$46
Jan-20-26ReiteratedNorthland Securities$40 → $50
Jan-12-26ReiteratedHC Wainwright & Co.Buy$35 → $48
Dec-03-25ReiteratedMorgan Stanley$28 → $36
Oct-31-25ReiteratedCraig-HallumBuy$34 → $41
Oct-31-25ReiteratedNorthland Securities$30 → $40
Oct-30-25ReiteratedHC Wainwright & Co.Buy$35
Aug-27-25ReiteratedCraig-HallumBuy$20 → $34
Mar-06-25ReiteratedPiper SandlerOverweight$15 → $13
Latest News
Aug-04-26
Aug-04-2601:21PM
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlookzacks.com
Aug-03-26
Aug-03-2603:44PM
Supernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This DealSeekingAlpha
03:15PM
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)prnewswire.com
12:14PM
Supernus Pharmaceuticals (SUPN) Announces Transformative Merger with Indivior (INDV)gurufocus.com
10:44AM
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenuebenzinga.com
10:44AM
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.com
08:46AM
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimateszacks.com
07:33AM
Supernus, Indivior merge to strengthen neuroscience drug portfolioreuters.com
06:31AM
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidanceglobenewswire.com
Jul-23-26
Jul-23-2610:00AM
Indivior to Report Second Quarter 2026 Financial Results and Host Webcastglobenewswire.com
Jul-21-26
Jul-21-2610:32AM
Billionaire Investor Howard Marks' Top 5 Holdings: A Buy at These Prices?247wallst.com
Jul-17-26
Jul-17-2610:00AM
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength ScoreChartMill
Jun-29-26
Jun-29-2609:56AM
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainablezacks.com
Jun-18-26
Jun-18-2608:49AM
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46Benzinga
Company

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,2911,2391,1881,093901791647785960
Cost of Goods Sold Incl. D&A21824623117415112797140135
Gross Profit1,073993957919750664550645825
Selling, General and Administrative Excl. Other570634618569469431649395444
Research and Development74971071167452405364
Other Operating Expense-1-3200390288-3217190
Operating Income43026532-156-81213-156178317
Interest Expense404541352926242231
Unusual Expense
—————————
Non-Operating Income (Expense)-95192342213724-21
Net Income Before Taxes29523914-149-89190-173180266
Income Taxes442911-20-44-15-25463
Consolidated Net Income2512102-129-44205-148134263
Net Income From Continuing Operations2512103-129-45205-148134263
Net Income2512102-129-44205-148134263
EPS (Recurring)2.011.680.020.01-0.371.38-1.080.951.81
EPS (Basic, Before Extraordinaries)2.011.680.020.01-0.371.38-1.080.951.81
EPS (Diluted)1.981.640.020.01-0.371.31-1.080.921.75
EBITDA35230484-99-46238-123230310
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio18.4321.88828.671,082.98—13.17—2.833.86
Price To Sales Ratio3.533.621.381.913.363.181.670.481.02
Gross Margin83.1180.1580.5684.0883.2483.9485.0182.1785.94
Operating Margin33.3121.392.69-14.27-8.9926.93-24.1122.6833.02
Net Margin19.4416.950.17-11.80-4.8825.92-22.8717.0727.40
Shares Outstanding125125132137139146147146145
Market Capitalization4,5634,4851,6412,0923,0232,5191,080380979
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$46.42$36.48$26.54$16.61$6.67● Close Price0.00M0.52M1.03M1.55M2.06MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Heidbreder ChristianChief Scientific OfficerJul 10 '26Sale41.1418,586764,628209,337Jul 13
Ciaffoni JosephChief Executive OfficerJun 22 '26Option Exercise0.001,266,90301,402,879Jun 23
Heidbreder ChristianChief Scientific OfficerJun 11 '26Sale38.0618,586707,383227,923Jun 12
Preblick RyanChief Financial OfficerJun 08 '26Sale37.7036,0001,357,200284,751Jun 10
Preblick RyanChief Financial OfficerMar 14 '26Option Exercise0.006,3020323,594Mar 17
Ryan BarbaraDirectorMar 13 '26Buy31.0982495,724Mar 13
Ryan BarbaraDirectorMar 09 '26Buy32.56311,0095,716Mar 11
Kingsley Stuart ADirectorMar 06 '26Buy31.8694029,9535,582Mar 11
Anderson Woodrow DChief Accounting OfficerMar 03 '26Option Exercise0.0048,285029,657Mar 05
Preblick RyanChief Financial OfficerMar 03 '26Option Exercise0.00200,4590317,292Mar 05
Burris Jeffrey WChief Legal OfficerMar 03 '26Option Exercise0.00184,1930107,550Mar 05
Heidbreder ChristianChief Scientific OfficerMar 03 '26Option Exercise0.00234,1090292,306Mar 05
Ryan BarbaraDirectorJan 05 '26Buy35.3977527,4291,963Jan 07
Humphreys KeithDirectorJan 05 '26Buy35.3977527,4295,802Jan 07
NINIVAGGI DANIEL ADirectorJan 05 '26Buy35.3977527,42916,923Jan 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.